Gogtay NJ, et al. - Researchers here investigated a recombinant human monoclonal antibody (SII RMAb) in a post-exposure prophylaxis (PEP) regimen in comparison to a human rabies immunoglobulin (HRIG)-containing PEP regimen. In this study, a PEP regimen containing SII RMAb proved safe and was non-inferior to HRIG PEP in RVNA production. They observed the novel monoclonal to be a safe and potent alternative for the passive component of PEP. It seemed to have potential for significantly improving the management of bites from suspected rabid animals.